<DOC>
	<DOCNO>NCT01530438</DOCNO>
	<brief_summary>Amyotrophic lateral sclerosis ( ALS ) neurodegenerative disease involve motor structure , previously think , also brain area deal cognition well part limbic system . Clinical , image pathological evidence suggest ALS fronto-temporal dementia ( FTD ) several feature common , two disease could two end pathological continuum .</brief_summary>
	<brief_title>Study Cognitive Emotional Disorders Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description>Objectives : investigator aim study clinical profile magnitude cognitive disturbance , measure brain metabolism assess cerebral atrophy patient ALS . The relationship cognitive , metabolic anatomical data determine correlation method . In addition , pathological study carry deceased patient give consent advance , order quantify neuronal loss UBIs . Methods : investigator plan recruit 60 patient ALS , 10 patient ALS/FTD ( diagnosis dementia rest clinical data formal neuropsychological test ) 20 normal control subject . The ALS patient divide 2 subset basis preliminary neuropsychological work-up , accord presence absence `` subclinical cognitive impairment '' define abnormal score test meet criterion dementia . In second test session carry time , comprehensive assessment memory , behaviour emotional change do . All subject undergo morphological magnetic resonance imaging ( MRI ) , resting-state functional MRI 18-fluorodeoxyglucose positron emission tomography ( 18FDG-PET ) . Whenever possible , second test session carry 9 12 month later order quantify cognitive deterioration , , find early predictor evolution towards dementia . In deceased patient , location extent neuronal loss determine , well location number UBIs . Results clinical relevance : study intend improve knowledge clinical phenotype ALS , particularly learn extent cognitive , behavioural emotional change disease . This could turn shed light relationship ALS FTD .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>All participant : study level &gt; 7 year mother tongue : french signature inform consent protocol accord Comité de Protection de Personnes medical , neurological , neuroradiological neuropsychological approfondis accord specific inclusion non inclusion criterion spécifiques population Patients ALS : 18 80 year old Diagnostic define probable accord review criterion El Escorial . Patients ALS / FTD : 18 8O year old Diagnostic define probable accord El Escorial review criterion diagnostic frontaltemporal dementia accord Lund et Manchester criterion . Control Subjects : 45 75 year old DRS ≥ 130 BECK &lt; 8 All particpants : Major past history ( chronic pulmonary disease , cardiac disease , metabolic , haematological , endocrinological severe immunological , cancer ) ; Chronic use alcohol drug ; IRM contraindication Protected adult , person non affiliate social protection system wo n't able participate study . The inclusion participant another biomedical research protocol ( study 12 month inclusion ) non inclusion criterion . Patients SLA patient SLA / FTD Severe bulbar disorder Severe restrictive respiratory insufficiency ( VC &lt; 50 % ) orthopny Communication disorder motor origin ( non assessable test ) Control Subjects : Pregnant nursing woman Unability submit study medical followup geographic psychiatric reason ( previous ongoing ) . DRS score &lt; 130 Depressive syndrome ( BECK ) ≥ 8</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Amyotrophic lateral sclerosis</keyword>
</DOC>